CTIS2023-508058-24-01招募中1 期
LCB-2301-001
ovImmune S.A.0 个研究点目标入组 12 人开始时间: 2024年2月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCEROCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERCTIS2023-508058-24-00ovImmune S.A.12
进行中（未招募）
1 期
A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust MitesCTIS2022-500660-35-00Astellas Pharma Global Development Inc.28
进行中（未招募）
1 期
Conducting a quality study of the medicinal product - Vortioxetineo therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-509946-36-00CCDRD Cooperative Clinical Drug Research and Development AG36
进行中（未招募）
1 期
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphomaewly diagnosed aggressive B-cell lymphoma (a-BCL)MedDRA version: 20.1Level: LLTClassification code: 10080217Term: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10023699Term: Large B-cell lymphoma subtype primary mediastinal (Thymic) large B-cell lymphoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065863Term: Anaplastic large-cell lymphoma primary cutaneous type Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10071977Term: Anaplastic lymphoma kinase gene mutation Class: 100000004850CTIS2023-506094-35-00Celgene Corp.174
进行中（未招募）
1 期
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.Cardiac arrhythmiasMedDRA version: 20.0Level: HLGTClassification code: 10007521Term: Cardiac arrhythmias Class: 10007541CTIS2023-509086-20-00Armgo Pharma Inc.8